Compass Therapeutics Inc. (CMPX) is scheduled to host a webcast on Tuesday, April 1, 2025, at 8:00 AM ET to review top-line clinical data from its ongoing COMPANION-002 clinical trial.
COMPANION-002 is a phase II/III trial evaluating the company's lead drug candidate Tovecimig plus paclitaxel against paclitaxel alone in patients with previously treated, unresectable advanced Metastatic or Recurrent Biliary Tract Cancers. This study completed enrollment of the planned 150 patients last August.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.